Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Obtaining mode and application of borrelia burgdorferi flagellin FlaB antibody

A flagellin and Borrelia technology, applied in application, immunoglobulin, antibacterial immunoglobulin, etc., can solve the problem of not yet developed an effective vaccine, and achieve the effect of saving antigen, high titer, and time.

Inactive Publication Date: 2019-01-04
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

An effective vaccine has not yet been developed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Obtaining mode and application of borrelia burgdorferi flagellin FlaB antibody
  • Obtaining mode and application of borrelia burgdorferi flagellin FlaB antibody
  • Obtaining mode and application of borrelia burgdorferi flagellin FlaB antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0033] 1. Research materials

[0034] 1. Experimental animals

[0035] The male Balb / c mice (8-12 weeks old) used in this study were from the Experimental Animal Center of the Institute of Medical Biology, Chinese Academy of Medical Sciences, the experimental animal production license [SCXX (Dian) K2017-0002], the use license [ SYXK (Dian) 2014-0002]. All animal use procedures were reviewed and approved by the Experimental Animal Ethics Committee of Medical Biology, Chinese Academy of Medical Sciences.

[0036] 2. Strains: Borrelia Burgdorferi B31 strain (hereinafter referred to as 4680) and Borrelia hermsii HS1 strain (hereinafter referred to as 5251) were purchased from NTCC.

[0037] 3. Experimental reagents

[0038] 1) Antibody: Anti-mouse IgG antibody (Cell Signaling Technology, Cat#7076P2), AlexaFluor-488 labeled anti-mouse IgG antibody (Abcam, Cat#ab150113).

[0039] 2) Immune adjuvant: QuickAntibody-Mouse5W (Beijing Boaolong Immunotechnology Co., Ltd., Cat#KX021004...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to preparation and application of a borrelia burgdorferi flagellin FlaB antibody. By means of a PCR method, a gene segment of FlaB is obtained from a borrelia burgdorferi genomethrough amplification, cloned into a prokaryotic expression vector pET30a containing a histidine tag and then transferred into escherichia coli BL21 competent cells. Induction expression is carried out through IPTG, affinity purification is performed to obtain FlaB protein, immunized mice obtain the borrelia burgdorferi flagellin FlaB antibody, and a solid foundation is laid for detection and deepresearch of borrelia burgdorferi.

Description

technical field [0001] The invention relates to the field of biological immunity, in particular to a method for preparing an antibody to phologellin FlaB, and more specifically to the application of the prepared antibody to detect Borrelia by different immunological methods. technical background [0002] Relapsing fever is an infectious disease caused by Borrelia bacteria infection with lice and ticks as the medium (Schwan, T.G. and J.Piesman, Vector interactions and molecular adaptations of lymedisease and relapsing fever spirochetes associated with transmission byticks. (2): p.115-21; Cutler, S.J., Possibilities for relapsing fever reemergence. Emerg Infect Dis, 2006.12(3): p.369-74). Most patients develop clinical reactions within 5 to 15 days after infection, including sudden cold, hot, headache, muscle or joint pain, and nausea (Ramos, J.M., et al., Results of a 10-year survey of louse -borne relapsing fever in southern Ethiopia: a decline in endemicity.Ann Trop Med Pa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/12C07K16/06C07K14/20C12N15/31C12N15/70G01N33/569
CPCC07K14/20C07K16/065C07K16/1207C12N15/70G01N33/56911G01N2333/20Y02A50/30
Inventor 刘红旗时宇陆巍李昕潼张静陶玉芬刘建生
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com